Arthanib 5 mg

● DAR143-0692-058
● Brand Name: Arthanib
● General Name :Tofacitinib
● Strength 5 mg
● Therapeutic Group Anti Rheumatic


Each film-coated tablet contains Tofacitinib Citrate INN 8 mg original to Tofacitinib 5 mg.
Tofacitinib is an oral Janus kinase (JAK) asset for the treatment of rheumatoid arthritis and psoriatic arthritis. Tofacitinib inhibits JAK-dependent cytokine signaling. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor relations on the cellular membrane. JAKs phosphorylate and spark Signal Transducers and Activators of Recap (STATs) which modulate intracellular exertion including gene expression. Tofacitinib prevents the phosphorylation and activation of STATs, therefore, downregulating the product of cytokines by inhibiting JAK.
Rheumatoid Arthritis Arthanib/ Arthanib XR Tablet is indicated for the treatment of adult cases with moderate to severe rheumatoid arthritis. It may be used as monotherapy or in combination with methotrexate or other nonbiologic complaint-modifying antirheumatic medicines (DMARDs). Psoriatic Arthritis Arthanib/ Arthanib XR Tablet is indicated for the treatment of adult cases with active psoriatic arthritis. It may be used in combination with methotrexate or other nonbiologic complaint-modifying antirheumatic medicines (DMARDs). Ulcerative Colitis Arthanib/ Arthanib XR Tablet is indicated for the treatment of adult cases with relatively to oppressively active ulcerative colitis
Lozenge & Administration
Rheumatoid Arthritis & Psoriatic Arthritis cases The recommended cure is Arthanib 5 mg doubly diurnal or Arthanib XR 11 mg formerly daily with or without food. Ulcerative colitis cases The recommended cure is Arthanib10 mg doubly daily for at least 8 weeks; also Arthanib 5 or 10 mg doubly daily
Contraindicated in cases with known acuity to Tofacitinib or any other element of this product. It’s contraindicated in severe hepatic disabled cases.
Warning & Preventives
Avoid the use of Tofacitinib during an active serious infection, including localized infections. Use with caution in cases that may be at increased threat of Gastrointestinal PerforationsAvoid the use of Tofacitinib coincidently with Immunizations – Live vaccines. Storage Store below 300 C in a dry placecover from light and humidityKeep out of the reach of children.
Side goods
The most generally reported adverse responses are upper respiratory tract infections, headache, diarrhea, and nasopharyngitis.
Medicine commerce
Tofacitinib exposure is increased when coadministered with potent impediments of cytochrome P450 (CYP) 3A4 (e.g., ketoconazole) & specifics that affect both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole). Tofacitinib exposure is dropped when coadministered with potent CYP3A4 corrupters (e.g., rifampin). There’s a threat of added immunosuppression when Tofacitinib is coadministered with potent immunosuppressive medicines (e.g., azathioprine, tacrolimus, cyclosporine). The use of Tofacitinib in combination with birth DMARDs or potent immunosuppressants similar to azathioprine and cyclosporine isn’t recommended.
Use in special groups
Use in gestation Gestation Order C. There are no acceptable and well-controlled studies on pregnant women. Tofacitinib should be used during gestation only if the implicit benefit justifies the implicit threat to the fetus. Use in lactation It isn’t known whether Tofacitinib is excreted in mortal milk. A decision should be made whether to discontinue nursing or to discontinue the medicinetaking into account the significance of the medicine for the mama. Pediatric use The safety and effectiveness of Tofacitinib in pediatric cases haven’t been established. Hepatic impairment No cure adaptation is needed in cases with mild hepatic impairment. For moderate hepatic impairment case‘s recommended cure is Tofacitinib 5 mg formerly daily. The use of Tofacitinib in cases with severe hepatic impairment isn’t recommended. Renal impairment No cure adaptation is needed in cases with mild renal impairment. For cases with moderate and severe renal impairment recommended cure is Tofacitinib 5 mg formerly daily.
Each box contains 10’s tablets in an all-alu fester pack.


There are no reviews yet.

Be the first to review “Arthanib 5 mg”

Your email address will not be published.